Abstract Aims Bioresorbable vascular scaffolds (BVSs) have been studied in chronic
coronary artery disease, but not in acute ST-segment elevation myocardial infarction …

Aims: In this multicentre prospective registry we sought to evaluate the immediate and
midterm clinical outcomes following single or multiple overlapping bioresorbable vascular …

Aims We evaluated the feasibility and the acute performance of the everolimus-eluting
bioresorbable vascular scaffolds (BVS) for the treatment of patients presenting with ST …

Aims Recent studies have demonstrated favourable clinical outcomes for the everolimus-
eluting bioresorbable vascular scaffold (BVS) ABSORB™ in patients with stable coronary …

Objectives The purpose of this study was to describe the multimodal outcome 12 months
after implantation of coronary bioresorbable scaffolds (BVS) for the treatment of patients with …

Objectives To evaluate safety and efficacy of the everolimus-eluting bioresorbable scaffold
(BVS) in patients with ST-segment elevation myocardial infarction (STEMI). Background …

Objective of this study was to assess the clinical performance of bioresorbable vascular
scaffold (BVS) compared to everolimus-eluting stent (EES) in subjects with ST-segment …

Background Bioresorbable vascular scaffolds (BVS) have become an emerging tool to treat
coronary artery disease. However, the current use of BVS is still widely restricted to stable …

Objectives: The purpose of this study was to compare the 1-year outcome between
bioresorbable vascular scaffold (BVS) and everolimus-eluting metallic stent (EES) in ST …

Aims: The safety of BVS implantation in patients with a high risk for early thrombotic
complications has not been studied. We report on the outcomes of patients with acute …